Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced that enrollment in the US RESiN Registry has reached a milestone of 1,650 patients and ...

Moreover, those patients treated with SIR-Spheres Y-90 resin microspheres who reported treatment-related side effects experienced a median of only 5 such events over the course of the SARAH study, ...

- WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of ...

Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...